Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Swedish Orphan Biovitrum Ab (OP: BIOVF ) 31.38 UNCHANGED Streaming Delayed Price Updated: 10:30 AM EST, Nov 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Swedish Orphan Biovitrum Ab Merck Virus Treatment Shows 60.4% Effectiveness, Reduces Certain Infections In Infants October 18, 2024 Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV. Via Benzinga Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases August 08, 2024 Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan for C3 glomerulopathy and IC-MPGN. The study met primary and secondary... Via Benzinga Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants October 16, 2023 As the respiratory virus season kicks off, healthcare providers are racing against time to offer Pfizer Inc's (NYSE: PFE) vaccine, Abrysvo, to pregnant patients and Sanofi SA's (NASDAQ: Via Benzinga Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon June 09, 2023 The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) nirsevimab has a favorable benefit-risk profile t Via Benzinga Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study May 25, 2023 Via Benzinga Sanofi's Hemophilia Candidate Goes Under Priority FDA Review August 30, 2022 Via Benzinga ADC Therapeutics, Sobi Ink European Licensing Pact For Lymphoma Drug July 08, 2022 Via Benzinga Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet May 11, 2023 Investors are on the hunt for undervalued, underfollowed and emerging stocks and retail traders have countless methods at their disposal to uncover new information. For some, this may be overwhelming. Via Benzinga Why Shares of CTI BioPharma Are Soaring Wednesday May 10, 2023 A buyout offer from Swedish Orphan Biovitrum drove up the stock's price. Via The Motley Fool European Swedish Orphan Biovitrum To Acquire CTI BioPharma For $1.7B May 10, 2023 Swedish Orphan Biovitrum AB (OTC: BIOVF) has agreed to acquire CTI BioPharma (NASDAQ: CTIC) for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of Via Benzinga Selecta, SOBI's Chronic Refractory Gout Program Meets Primary Goal, US Submission Expected Next Year March 21, 2023 Via Benzinga Veru Stock Could Retrace Week's 45% Gain As FDA Panel Votes Against COVID-19 Drug November 10, 2022 Veru Inc. Via Benzinga Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants November 04, 2022 Via Benzinga The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death July 11, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga SOBI-Sanofi Partnered Hemophilia Therapy Shows Superior Bleed Protection Than Prior Prophylaxis July 11, 2022 Via Benzinga The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug July 08, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Sanofi-SOBI Hemophilia Candidate Aces Late-Stage Study In Pretreated Patients March 09, 2022 Swedish Orphan Biovitrum AB (OTC: BIOVF) and Sanofi SA (NASDAQ: SNY) have announced topline results from the XTEND-1 phase 3 study of efanesoctocog alfa (BIVV001)... Via Benzinga Apellis - Sobi's Pegcetacoplan Wins European Approval For Rare Blood Disorder December 15, 2021 The European Commission has approved Swedish Orphan Biovitrum AB (OTC: BIOVF) - Apellis Pharmaceuticals Inc's (NASDAQ: APLS) Aspaveli (pegcetacoplan... Via Benzinga AstraZeneca Blocks SOBI's $8B Buyout, Advent Withdraws The Bid - Report December 03, 2021 AstraZeneca Plc (NASDAQ: AZN) blocked an $8 billion takeover of Swedish Orphan Biovitrum AB (OTC: BIOVF) by withholding its 8% stake in SOBI from a buyout offer by... Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
